Neurotechnology Startup Funding 2025-2026

What are all the funding deals in the neurotechnology market from August 2025 to July 2026?

The table below lists every disclosed equity round raised by pure-play neurotechnology companies between August 2025 and July 2026. We count as pure-play neurotechnology companies those that directly measure, stimulate, or computationally interface with the human nervous system for clinical or validated functional outcomes.

Each row shows the company, what it does, its category, the deal date, the funding stage, the round size, the region, the main investors, and the announcement source. For a wider view of how neurodevices, BCIs, neuromodulation, and neurodiagnostic tools fit together, we cover the market in our Neurotechnology market report.

How active has fundraising been in the neurotechnology market?

As of July 2026, fundraising in the neurotechnology market has been active but selective. Over the past 12 months, the market recorded 26 disclosed equity rounds and $1.63B in total capital raised.

The deal cadence looks healthy at first glance. Across August 2025 through June 2026, the market averaged 2.36 disclosed deals per month, with a median of 2 deals per month.

Dollar flow was much less stable than deal flow. The neurotechnology market averaged $148.02M raised per month, but the monthly median was only $73.46M, showing how large rounds lifted the average.

June 2026 had no qualifying disclosed equity deal in the dataset. That does not mean activity stopped, but it does show that public financing momentum arrived in bursts rather than smoothly.

If you want to go deeper on company activity and timing, see our market report on neurotechnology funding.

How concentrated has fundraising been in the neurotechnology market?

As of July 2026, fundraising in the neurotechnology market has been highly concentrated at the top. Over the past 12 months, the top 10 deals captured 82.48% of all disclosed capital.

The single largest round represented 15.48% of total capital, while the top 3 deals reached 41.89%. The top 5 deals reached 56.93%, meaning more than half the market came from only five financings.

This concentration matters because the headline total can make the market look broader than it is. The neurotechnology market had 26 deals, but most dollar momentum came from a small group of platform-scale companies.

That does not make the funding signal weak. It means the signal should be read as concentrated conviction, not as proof that every neurotechnology subcategory is liquid.

How much of the neurotechnology funding signal is driven by outliers?

As of July 2026, a large share of the neurotechnology funding signal is driven by outliers. Over the past 12 months, 12 of 26 disclosed deals were $50M or larger.

Those large rounds represented 46.15% of deal count, but they explained most of the market’s capital momentum. The dataset becomes much smaller when rounds above $50M are excluded.

Total capital raised excluding rounds above $50M was only $176.19M. That figure is barely above one mid-sized growth round, so it should be read as the market’s underlying small-and-mid-round base.

The median round was $29M, while the average was $62.62M. That gap is the cleanest warning that the average round size is not typical.

Is the neurotechnology market broad with many targets, or narrow with few fundable companies?

As of July 2026, the neurotechnology market is moderately broad by company count but narrow by capital allocation. Over the past 12 months, 25 unique companies raised 26 disclosed equity rounds.

The high unique-company count means the neurotechnology market is not just one or two companies recycling the same capital story. Only Beacon Biosignals appears twice in the dataset, through its Series B and later extension.

But the dollar distribution is still narrow. The top 10 deals captured 82.48% of capital, so most companies did not meaningfully shape the market total.

The practical reading is simple. Neurotechnology has many fundable technical paths, but only a few companies received platform-scale checks during this window.

Is neurotechnology mostly an early-stage formation market or a late-stage scaling market?

As of July 2026, the neurotechnology market is both an early-stage formation market and a late-stage scaling market. Over the past 12 months, early-stage rounds captured 42.83% of capital, while late-stage rounds captured 50.64%.

Seed rounds were the largest stage by deal count, with 9 of 26 disclosed deals. But Seed capital was heavily distorted by Merge Labs, whose $252M seed round made early-stage dollars look much larger.

Series C, Series D+, and Growth Equity together represented only 7 deals. Those 7 deals captured $824.50M, which confirms that late-stage neurotechnology funding is selective but large when companies clear proof thresholds.

Unknown-stage rounds added $106.28M, or 6.53% of disclosed capital. These rounds matter, but they do not change the core split between formation and scaling.

For more context on stage mix and maturity, read our full market deck on neurotechnology.

Which categories attract the most investor attention in neurotechnology?

As of July 2026, Brain Computer Interfaces and Neuromodulation Devices attract the most investor attention in neurotechnology. Together, they account for 19 of 26 disclosed deals and $1.35B raised over the past 12 months.

Brain Computer Interfaces led the neurotechnology market with 10 deals and $962.46M raised. That equals 38.46% of deals and 59.11% of total capital.

Neuromodulation Devices followed with 9 deals and $384.63M raised. This category was almost as active by count, but its 23.62% capital share was far lower than BCI’s.

Neuro Monitoring Tools had 4 deals and $179.50M, while EEG Analytics Platforms had 2 deals and $97M. Clinical Neurosoftware barely registered, with 1 seed deal and $4.60M.

Which categories attract disproportionately large checks in the neurotechnology market?

As of July 2026, Brain Computer Interfaces attract disproportionately large checks in the neurotechnology market. Over the past 12 months, BCI represented 38.46% of deals but 59.11% of total capital.

The category’s capital-share-to-deal-share ratio was 1.54, the strongest in the dataset. That means investors were not merely funding more BCI companies; they were writing larger checks into the category.

Neuromodulation Devices had a ratio of 0.68, and Neuro Monitoring Tools had a ratio of 0.72. Both categories were credible, but they did not receive the same capital premium.

EEG Analytics Platforms had a ratio of 0.77, while Clinical Neurosoftware had only 0.07. The market clearly rewarded direct signal, stimulation, and interface control more than software-only neurological workflows.

Which geographies matter most for fundraising in the neurotechnology market?

As of July 2026, North America matters most for fundraising in the neurotechnology market. Over the past 12 months, the region captured $1.29B, or 79.17% of all disclosed capital.

North America also led by deal count, with 15 of 26 disclosed rounds. Its average deal size was $85.93M, and its median round size was $55M.

Europe ranked second with 7 deals and $196.84M raised, equal to 12.09% of capital. Its median round was only $7.50M, showing how a few larger deals carried the region.

Asia-Pacific produced 4 deals and $142.35M, equal to 8.74% of capital. That makes the region visible, but still episodic compared with North America’s repeated financing cadence.

We cover the regional pattern in more depth in our deeper analysis of the neurotechnology market.

Is the neurotechnology opportunity set broad or concentrated in one hub?

As of July 2026, the neurotechnology opportunity set is concentrated in one dominant hub with two smaller secondary regions. Over the past 12 months, North America alone captured nearly four-fifths of disclosed capital.

Europe and Asia-Pacific together accounted for 12.09% and 8.74% of capital, respectively. They show meaningful company activity, but not enough repeated large rounds to challenge North America.

Latin America, the Middle East, and Africa had no qualifying disclosed equity deals in the dataset. That absence matters because neurotechnology depends on specialized clinical, regulatory, manufacturing, and investor ecosystems.

The geography signal is therefore not only about headquarters. It also points to where clinical infrastructure, medical-device expertise, and specialized capital are densest.

Is neurotechnology a market of small experiments or scaled financings?

As of July 2026, neurotechnology is a market with both small experiments and scaled financings, but dollars are controlled by scaled financings. Over the past 12 months, 12 disclosed rounds were $50M or larger.

The round-size distribution shows the split clearly. Four deals were below $5M, 6 were between $5M and below $20M, 4 were between $20M and below $50M, and 12 were $50M or larger.

Six deals exceeded $100M, representing 23.08% of all disclosed rounds. That is a strong megadeal signal for a market that still contains many early clinical and prototype-stage companies.

The median round of $29M is the better proxy for normal fundability. The $62.62M average is useful, but it is pulled upward by very large BCI, neuromodulation, and monitoring rounds.

For a fuller view of round-size tiers, see our neurotechnology market report covering deal distribution.

How important are follow-on rounds in the neurotechnology market?

As of July 2026, follow-on rounds are important in the neurotechnology market, but first financings still matter. Over the past 12 months, the dataset includes a mix of new-company formation and repeat-backed clinical or platform companies.

Many of the largest rounds were follow-ons, including Synchron, Science Corporation, SetPoint Medical, Cognito Therapeutics, Nudge, CoMind, Beacon Biosignals, and ONWARD Medical. These companies generally had clearer evidence, platform claims, or commercialization paths.

First financings were more common among smaller or newer bets, but Merge Labs is the major exception. Its $252M seed round turned first financing into a major part of the dollar story.

This means follow-on status should not be used alone as a quality filter. In neurotechnology, investors also respond to architecture, evidence type, clinical path, and strategic interface potential.

Who are the investors that appear the most in neurotechnology fundraising?

As of July 2026, repeat investor disclosure in the neurotechnology market is limited. Over the past 12 months, Khosla Ventures was the only investor clearly identified as appearing in more than one disclosed deal.

Khosla Ventures appeared in Synchron and Science Corporation, which are both high-profile neural-interface companies. That repeat pattern points toward conviction in platform-style BCI rather than broad coverage of every neurotechnology category.

Investor disclosure is incomplete across several rounds. Many announcements list only selected participants, undisclosed investors, legal advisers, or total round size without a full cap table.

One important caveat is that round participation does not reveal individual check size. Any investor ranking should be read as participation frequency, not dollars personally committed.

If you want to track investor positioning over time, we include more context in our market report covering neurotechnology investors.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.